Drug Search Results
More Filters [+]

HMPL-004

Alternative Names: hmpl-004, hmpl004, hmpl 004
Latest Update: 2024-04-03
Latest Update Note: PubMed Publication

Product Description

HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses

Mechanisms of Action: TNF Inhibitor,IL1 Inhibitor,IL6 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: HUTCHMED
Company Location: HONG KONG K3 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HMPL-004

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Colitis, Ulcerative

Phase 2: Crohn Disease|Colitis, Ulcerative

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2017-599-00AU1

P1

Terminated

Crohn Disease|Colitis, Ulcerative

2018-11-19

22%

HMPL-004-03

P3

Terminated

Colitis, Ulcerative

2014-10-01

NATRUL-4

P3

Terminated

Colitis, Ulcerative

2014-10-01

81%

2013-003060-31

P3

Terminated

Colitis, Ulcerative

2014-08-13

Recent News Events